Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22864130 | 0.85 | MEN1 (0.57) | MEN1KMT2ACASP2 | |
| SCHEMBL12660513 | 0.85 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL13612101 | 0.84 | MEN1 (0.36) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL1402612 | 0.81 | KDM4E (0.32) | TSHRMEN1KMT2AKDM4E | |
| SCHEMBL12451661 | 0.81 | KDM4E (0.52) | ALDH1A1SMN1; SMN2TSHRKDM4E | |
| SCHEMBL275563 | 0.81 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL5916828 | 0.79 | EPHX1 (0.50) | TSHRMEN1KMT2AGAA | |
| SCHEMBL13784565 | 0.78 | MEN1 (0.32) | TSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL6551654 | 0.78 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL20280712 | 0.76 | POLB (0.42) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622512-B2 | Cationic hydrophilic siloxanyl monomers | BAUSCH & LOMB INCORPORATED (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080152540-A1 | PACKAGING SOLUTIONS | BAUSCH & LOMB INCORPORATED (US) | 2008-06-26 | — | — | US | disclosed |
| US-20070142583-A1 | Cationic hydrophilic siloxanyl monomers | ECR PHARMACEUTICALS CO., INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142583-A1 | Cationic hydrophilic siloxanyl monomers | STIM1, ILK, AAAS | ALDH1A1 2469/4885SMN1; SMN2 4422/4885TSHR 4704/4885 |
| US-20080152540-A1 | PACKAGING SOLUTIONS | AQP1, ARGLU1, CRYZ | ALDH1A1 4081/4885SMN1; SMN2 3337/4885TSHR 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.